Neratinib, 98.5%, a highly selective HER2 and EGFR inhibitor

Name: Neratinib, 98.5%, a highly selective HER2 and EGFR inhibitor | 698387-09-6
Brand: J&K Chemical
SKU: JK996304_10_MG
Price: 96.2 USD
Availability: OutOfStock

Cat. No JK996304_10_MG

Vendor: J&K Chemical

Product Information

Product Name

Neratinib, 98.5%, a highly selective HER2 and EGFR inhibitor

Brand Name

J&K

Product Number

996304

CAS

698387-09-6

Molecular Formula

C30H29ClN6O3

Molecular Weight

557.04

SDS Document

View/Download

Certificate of Analysis (COA)

COA not found

General Information

Synonyms

HY-32721

PubChem CID

9915743

IUPAC Name

(E)-N-4-3-chloro-4-(pyridin-2-ylmethoxy)anilino-3-cyano-7-ethoxyquinolin-6-yl-4-(dimethylamino)but-2-enamide

InChI Key

JWNPDZNEKVCWMY-VQHVLOKHSA-N

SMILES

CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)/C=C/CN(C)C

Safety Information

Storage Condition

Freezer -20℃

References Data Source From Pubchem

Breast cancer: taxonomy, distribution analysis, risk factors, predictive biomarkers, and modern treatment method

Publication Name: Apoptosis : an international journal on programmed cell death

Publication Date: 2026-02-20

DOI: 10.1007/s10495-026-02281-7

HER2 heterogeneity between primary cancers and brain metastases: a retrospective analysis of 185 matched pairs across multiple cancer types

Publication Name: Journal of Neuro-Oncology

Publication Date: 2026-02-20

DOI: 10.1007/s11060-026-05476-9

The evolving landscape of bench-to-bedside translation in the era of neoadjuvant platforms: perspectives and opportunities

Publication Name: Holistic Integrative Oncology

Publication Date: 2026-02-14

DOI: 10.1007/s44178-025-00219-8

Atrial fibrillation associated with tyrosine kinase inhibitors: A case–control study of real-world pharmacovigilance data

Publication Name: Naunyn-Schmiedeberg's Archives of Pharmacology

Publication Date: 2026-02-10

DOI: 10.1007/s00210-026-05078-2

Computational exploration of novel indanone-pyrazole fused schiff base scaffolds as potential EGFR inhibitors for anticancer therapy

Publication Name: Discover Chemistry

Publication Date: 2026-02-10

DOI: 10.1007/s44371-026-00503-0

Neratinib, 98.5%, a highly selective HER2 and EGFR inhibitor

Product Information

General Information

Safety Information

References Data Source From Pubchem

Breast cancer: taxonomy, distribution analysis, risk factors, predictive biomarkers, and modern treatment method

HER2 heterogeneity between primary cancers and brain metastases: a retrospective analysis of 185 matched pairs across multiple cancer types

The evolving landscape of bench-to-bedside translation in the era of neoadjuvant platforms: perspectives and opportunities

Atrial fibrillation associated with tyrosine kinase inhibitors: A case–control study of real-world pharmacovigilance data

Computational exploration of novel indanone-pyrazole fused schiff base scaffolds as potential EGFR inhibitors for anticancer therapy